🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lucence is extremely honoured to be a winner of the first-ever 2022 #WIPOGlobalAwards! On July 19, our CEO Dr. Min-Han Tan was presented with the award in Geneva, Switzerland. Grateful to World Intellectual Property Organization (WIPO) and its esteemed jurors for affirming Lucence’s mission and work! (Photo by: WIPO)

Prostate cancer is the 2nd leading cause of cancer death for men. Lucence and the National Cancer Centre Singapore are glad to announce the launch of a study for patients with #prostatecancer using #liquidbiopsy bit.ly/3r4NJxk #ProstateCancerAwarenessMonth

Visit our booth at the International Society of Liquid Biopsy #ISLB2022 conference in Miami, Florida October 21-22 to learn more about how LiquidHALLMARK® can help profile #cancer and its #immune microenvironment. #liquidbiopsy

Did you know ctRNA can detect gene #fusions missed by ctDNA? Accelerate drug development with serial non-invasive profiling of the circulating tumor microenvironment (TME) with #ctDNAandRNA Looking forward to meeting you this week at International Society of Liquid Biopsy #ISLB2022 Booth #20!

Lucence Staff Spotlight Meet Naing, our Software Engineering Lead at Lucence. He is responsible for building Lucence's clinical intelligence software and web applications to deliver best possible patient care. He achieved AWS Solutions Architect Professional while at Lucence.

We're excited to exhibit at #ESMOAsia22 in-person in #Singapore in a week! So glad to partner pharmas and physicians to improve patient access. Schedule a chat with us at calendly.com/lucence, or visit us at Booth #E207 at Suntec Singapore on 2-4 December 2022.

See you at Booth E207 soon! #ESMOAsia22

A wrap on ESMO Asia Congress 2022! Thank you to ESMO - Eur. Oncology for organising a wonderful conference.

Precision medicine test reports should be easy for physicians and patients to read. So glad to share our new report format which offers comprehensive and accessible LiquidHALLMARK® results to empower oncologists. Learn more using this video here! youtu.be/KVTFi3W6QYM

Year in Review We're thankful to help patients across the United States, Asia and Africa. And here's our deepest gratitude to all of you who make Lucence who we are. Thank you to our partners, investors, healthcare providers and most of all, to our patients, for trusting us!

Interested in how #mirrorbarcodes and #ctRNA can enable multi-cancer early detection? We're committed to this mission and excited to share. Our CEO Min-Han Tan and CFO Vee Kiet Chan are looking forward to chat at #JPM2023!

Yaw Bediako Founder and CEO Yemaachi and among New African's 100 Most Influential Africans, is on a mission to fix unequal healthcare for patients with African ancestry. Such a moment for this genomics partnership born out of our work together at Van Andel Institute (VAI) !

So glad to be presenting research at the 1st AACR Special Conference for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Austin, Texas. See you there!

We're pleased to announce that our LiquidHALLMARK assay has been granted Medicare coverage for lung cancer. Deeply grateful for this opportunity to contribute to more patient care! lucence.com/lucencenews/lu…

Our sincerest thanks to Singapore Deputy Prime Minister Heng Swee Keat for gracing the launch of LucenceINSIGHT™ at our US headquarters. Press Release: lucence.com/lucencenews/lu… #NoPatientLeftBehind

Besides the regular ASCO #ASCO23 program, there are a number of interesting sponsored presentations. Join me for dinner & discussion about #ctRNA being a game changer for #lungcancer detection and treatment selection #liquidbiopsy. June 3 - 6:30pm CT, hosted by @lucencehealth

Read 5 of our co-authored #ASCO23 abstracts here on multi-cancer early detection and ctDNA/ctRNA : lnkd.in/gNhqERfk

We were extremely honored to share our story with Singapore Prime Minister leehsienloong during his #APEC2023 visit to the Bay Area. It's been a 6-year journey to securing US Medicare coverage for our #liquidbiopsy tech to help US patients! Photo credits: Enterprise Singapore

We're pleased to announce that our LiquidHALLMARK assay has been granted Medicare coverage for all types of advanced solid tumors. Grateful for this milestone that allows us to contribute to more patient care! lucence.com/lucencenews/lu…

We're honored to collaborate with Mayo Clinic Laboratories to expand liquid biopsy access to more cancer patients.